MRNS Projected Dividend Yield
Marinus Pharmaceuticals Inc ( NASDAQ : MRNS )Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. Co. is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Co.'s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. 20 YEAR PERFORMANCE RESULTS |
MRNS Dividend History Detail MRNS Dividend News MRNS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |